Overall rank by patents
#24,392
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, active 2020–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
GSK holds 11 US patents across 4 technology areas, rank #24,392 of 50,000 tracked assignees.
GSK Consumer Healthcare SARL has been granted 11 US utility patents between 2020 and 2023, placing GSK Consumer Healthcare SARL at rank #24,392 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.8 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, GSK Consumer Healthcare SARL is one of the more focused assignees in the PatentsView dataset. By volume, GSK sits between GRI BIO, Inc. (11 patents, rank #24,388) and Guangzhou Construction Engineering Co., Ltd. (11 patents, rank #24,396) - the closest US assignees by grant volume. The composite Innovation Score of 26.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2023, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. GSK Consumer Healthcare SARL's 8.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GSK Consumer Healthcare SARL against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GRI BIO, INC.
11 patents
GRONINGER & CO. GMBH
11 patents
GS Elektromedizinische Geräte G. Stemple GmbH
11 patents
GSC SECRYPT, LLC
11 patents
GT METABOLIC SOLUTIONS, INC.
11 patents
GUANGDONG HUARUN PAINTS CO., LTD
11 patents
GUANGDONG UNILUMIN ENERGY SAVING TECHNOLOGY CO., LTD
11 patents
GUANGZHOU CONSTRUCTION ENGINEERING CO., LTD.
11 patents
GSK Consumer Healthcare SARL
11 patents
What this shows GSK holds 11 patents at rank #24,392, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
GSK's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 80% higher than 20% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 18.2% |
| 2021 | 4 | 36.4% |
| 2022 | 3 | 27.3% |
| 2023 | 2 | 18.2% |
Top 4 of 4 technology areas
Overall rank by patents
#24,392
Across all tracked assignees
26.5 out of 100
How to use this portfolio
GSK's 11 grants land it in the top 80% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.